2
Clinical Trials associated with PSMA-CART cell therapy(BRL Medicine Inc) / RecruitingEarly Phase 1IIT The Safety and Efficacy Evaluation of Enhanced Autologous PSMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Castration Resistant Prostate Cancer
This is one center, single-arm, open-label investigator initiated trial to assess the safety and efficacy of enhanced autologous PSMA chimeric antigen receptor T cells in the treatment for patients with refractory castration resistant prostate cancer, and the sample size is set to 7-18 subjects.
A Phase I Study to Evaluate the Safety and Efficacy of PSMA-CART Co-expressing LIGHT in Treating Patients With Castrate-Resistant Prostate Cancer (CRPC)
This is a single center, single arm Phase I study to establish the safety and efficacy of intravenously administered lentivirally transduced LIGHT-PSMA-specific CAR modified autologous T cells (PSMA-CART cells) in patients with CRPC.
100 Clinical Results associated with PSMA-CART cell therapy(BRL Medicine Inc)
100 Translational Medicine associated with PSMA-CART cell therapy(BRL Medicine Inc)
100 Patents (Medical) associated with PSMA-CART cell therapy(BRL Medicine Inc)
100 Deals associated with PSMA-CART cell therapy(BRL Medicine Inc)